Q&A
Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO
According to the lentiviral vector manufacturer, which supplies vectors for Novartis’ Kymriah, the market is growing – and could be worth $800m by 2026.
Archives for December 10, 2018